Severity, criticality, and fatality of the SARS-CoV-2 Beta variant-Reference-Cited by-同舟云学术

Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

Published:2021-10-17 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Abu-Raddad Laith J¹²³⁴,Chemaitelly Hiam¹²,Ayoub Houssein H⁵,Yassine Hadi M⁶⁷,Benslimane Fatiha M⁶⁷,Al Khatib Hebah A⁶⁷,Tang Patrick⁸,Hasan Mohammad R⁸,Coyle Peter⁶⁹¹⁰,AlMukdad Sawsan¹²,Al Kanaani Zaina⁹,Al Kuwari Einas⁹,Jeremijenko Andrew⁹,Kaleeckal Anvar Hassan⁹,Latif Ali Nizar⁹,Shaik Riyazuddin Mohammad⁹,Abdul Rahim Hanan F⁴,Nasrallah Gheyath K⁶⁷,Al Kuwari Mohamed Ghaith¹¹,Butt Adeel A³⁹,Al Romaihi Hamad Eid¹²,Al-Thani Mohamed H¹²,Al Khal Abdullatif⁹,Bertollini Roberto¹²

Affiliation:

1. Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

2. World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar

3. Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA

4. Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar

5. Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University; Doha, Qatar

6. Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar

7. Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar

8. Department of Pathology, Sidra Medicine, Doha, Qatar

9. Hamad Medical Corporation, Doha, Qatar

10. Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom

11. Primary Health Care Corporation, Doha, Qatar

12. Ministry of Public Health, Doha, Qatar

Abstract

Abstract Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab909/40672230/ciab909.pdf

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis;JMIR Public Health and Surveillance;2024-08-27

2. A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates;iScience;2024-07

3. Paradigm of immune dysregulation in coronavirus disease-2019 infection;Exploration of Immunology;2024-01-31

4. Integration of individualized and population-level molecular epidemiology data to model COVID-19 outcomes;Cell Reports Medicine;2024-01

5. The ACE2 receptor protein-mediated SARS-CoV-2 infection: dynamic properties of a novel delayed stochastic system;AIMS Mathematics;2024